Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Reader Login
Users Online :222
Small font sizeDefault font sizeIncrease font size
Navigate Here
     My Preferences 
     Manuscript submission

 


Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2019| April-June  | Volume 56 | Issue 2  
    Online since May 2, 2019

 
 
  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
 
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
EDITORIAL
“Financial audit of wastage of anticancer drugs: Pilot study from a tertiary care center of India”: A commentary
Fatih Safa Erenay, Susan Horton
April-June 2019, 56(2):99-100
DOI:10.4103/ijc.IJC_125_19  PMID:31062725
  854 432 -
HEAD AND NECK CANCER
Incidence, prevalence, and mortality associated with head and neck cancer in India: Protocol for a systematic review
Aayush Poddar, Ritchlynn Aranha, Madhav Madurantakam Royam, Kodiveri Muthukaliannan Gothandam, Ramesh Nachimuthu, Rama Jayaraj
April-June 2019, 56(2):101-106
DOI:10.4103/ijc.IJC_416_18  PMID:31062726
BACKGROUND: Head and neck cancer (HNC) is a heterogeneous tumor at various anatomic sites and one of the most common cancers in India. Published and existing reports and studies highlight an alarming increase in the incidence, prevalence, and mortality of HNC. Despite its high incidence, there is a dearth of more precise estimates of reliable epidemiological data pertaining to HNC in India. AIM: This protocol aims to conduct a full-scale systematic review and meta-analysis on the HNC epidemiology (incidence, prevalence, and mortality) in 29 states and 7 union territories of India. METHODS AND ANALYSIS: We will search for eligible published studies through PubMed, Scopus, Science Direct, MEDLINE, Web of Science, and Cochrane Review. Cancer registries such as (but not limited to) World Health Organization, International Agency for Research on Cancer, and the National Centre for Disease Informatics and Research-National Cancer Registry Program, which is maintained by the Indian Council of Medical Research, will be used for extracting relevant data using a standardized data collection form. The random-effects model of meta-analysis will be employed to aggregate the pooled estimates of relative ratios with 95% confidence intervals. Publication bias will be assessed using a funnel plot, and Egger's regression will be applied to test the symmetry of the funnel plot. DISCUSSION: This review will provide updated evidence of the current burden of HNC in India. This will guide future studies and cancer registry reports to provide holistically representative epidemiological data. SYSTEMATIC REVIEW REGISTRATION: In accordance with the guidelines, our systematic review protocol was registered with the International Prospective Register of Systematic Reviews and was assigned the registration number, CRD42017077482.
  839 330 -
BREAST CANCER
FISH and HER2/neu equivocal immunohistochemistry in breast carcinoma
Geeta Vikram Patil Okaly, Dipti Panwar, Kavitha Bidadli Lingappa, Prasanna Kumari, Abhishek Anand, Prashantha Kumar, Manju Hosur Chikkalingaiah, Rekha Vijay Kumar
April-June 2019, 56(2):119-123
DOI:10.4103/ijc.IJC_333_18  PMID:31062729
AIM: The aim of this study was to validate the role of fluorescence in situ hybridization (FISH) in investigating HER2/neu gene amplification (human epidermal growth factor receptor 2) in patients with HER2/neu equivocal breast cancer diagnosed on immunohistochemistry (IHC). MATERIALS AND METHODS: This was a retrospective study conducted from January 2013 to October 2017. A total of 134 patients diagnosed with invasive breast carcinoma and HER2/neu equivocal status on IHC were analyzed. Also, the cases for the years 2016 and 2017 formed a subgroup that was analyzed further to study the impact of pre-analytical factors on IHC and FISH results. RESULTS: A total of 134 women with HER2/neu IHC equivocal breast cancer were included in the study with a median age of 50 years (range 25–81). HER2/neu amplification by FISH was noted in 72 (54%) cases, whereas it was non-amplified in 52 (39%) cases. Ten cases were reported as equivocal even on FISH (ASCO/CAP 2013 guidelines). Polysomy 17 was noted in 55 cases (41%), of which 26 patients were≤50 years and 29 patients were >50 years of age. Twenty (36%) of these 55 cases showed HER2/neu amplification, whereas 26 (48%) cases were non-amplified and 9 (16%) cases were reported as equivocal on FISH. Also, more than half of the polysomy cases were hormone receptor negative. CONCLUSION: IHC is a good screening tool for negative and positive results. Any patient targeted for trastuzumab therapy should undergo confirmation of HER2/neu equivocal status by FISH analysis. We also suggest that if a non-classical FISH pattern is seen, the test should be repeated with a non-centromeric chromosome 17 reference locus probe for better treatment planning.
  613 162 -
HEAD AND NECK CANCER
Role of community health worker in a mobile health program for early detection of oral cancer
N Praveen Birur, Keerthi Gurushanth, Sanjana Patrick, Sumsum P Sunny, Shubhasini A Raghavan, Shubha Gurudath, Usha Hegde, Vidya Tiwari, Vipin Jain, Mohammed Imran, Pratima Rao, Moni Abraham Kuriakose
April-June 2019, 56(2):107-113
DOI:10.4103/ijc.IJC_232_18  PMID:31062727
Background: The global incidence of oral cancer occurs in low-resource settings. Community-based oral screening is a strategic step toward downstaging oral cancer by early diagnosis. The mobile health (mHealth) program is a technology-based platform, steered with the aim to assess the use of mHealth by community health workers (CHWs) in the identification of oral mucosal lesions. MATERIALS AND METHODS: mHealth is a mobile phone-based oral cancer-screening program in a workplace setting. The participants were screened by two CHWs, followed by an assessment by an oral medicine specialist. A mobile phone-based questionnaire that included the risk assessment was distributed among participants. On specialist recommendation an oral surgeon performed biopsy on participants. The diagnosis by onsite specialist that was confirmed by histopathology was considered as gold standard. All individuals received the standard treatment protocol. A remote oral medicine specialist reviewed the uploaded data in Open Medical Record System. Sensitivity, specificity, positive and negative predictive values were calculated. Inter-rater agreement was analyzed with Cohen's kappa coefficient (κ) test, and the diagnostic ability of CHWs, onsite specialist, and remote specialist was illustrated using receiver operating characteristic curve. RESULTS: CHWs identified oral lesions in 405 (11.8%) individuals; the onsite specialist identified oral lesions in 394 (11.4%) individuals; and the remote specialist diagnosed oral lesions in 444 (13%). The inter-rater agreement between the CHW and the onsite specialist showed almost perfect agreement with the κ score of 0.92, and a substantial agreement between CHW and remote specialist showed a score of 0.62. The sensitivity, specificity, positive and negative predictive values of CHWs in the identification of oral lesion were 84.7, 97.6, 84.8, and 97.7%, respectively. CONCLUSION: The trained CHWs can aid in identifying oral potentially malignant disorders and they can be utilized in oral cancer-screening program mHealth effectively.
  512 142 -
BREAST CANCER
Survival and treatment outcomes of metaplastic breast carcinoma: Single tertiary care center experience in Pakistan
Zarka Samoon, Madiha Beg, Romana Idress, Adnan A Jabbar
April-June 2019, 56(2):124-129
DOI:10.4103/ijc.IJC_731_18  PMID:31062730
BACKGROUND: Metaplastic breast carcinoma (MBC) is a rare disease with incidence of less than 1%. MBC present with a larger tumor size, less number of nodes involved, mostly undifferentiated triple negative tumors. We aimed to determine progression-free and overall survival and reported hospital-based incidence of MBC. MATERIAL AND METHODS: A retrospective closed Cohort study elicited data of 42 patients with MBC from January 2008 to December 2013; followed till August 2016. Kaplan-Meier method was applied to compute overall and progression-free survival analysis. Cox Proportional hazard ratios were computed to assess associations between survival and independent variables. RESULTS: Hospital-based incidence of MBC was 1.92% (42/2187), 95% CI [1.41-2.56]. The median age at tumor diagnosis was 54 years (range, 25–81 years). Thirty-nine (92.9%) patients had Grade III tumor. The most common histopathology was squamous (69%). The median tumor size was 4.5 cm (range, 0.8–17 cm). Nineteen (45.2%) patients had nodal involvement at diagnosis. Four patients (9.5%) had metastatic disease at presentation. Hormone receptors were positive in 19 (45.2%) patients. Her-2 neu receptor was positive in 9 (19%) patients. Sixteen (38.1%) patients had triple negative disease. Neoadjuvant and adjuvant chemotherapy was received by 10 (31.25%) and 19 (45.2%) patients respectively. Both median progression-free and overall survival was 38 months. CONCLUSION: Five-year progression-free and overall survival was 79.5% and 76.3%, respectively. We report better survival outcomes when compared to series described earlier despite our patient population presenting mostly with high grade, large tumors, and half of them exhibiting nodal and hormonal involvement.
  489 113 -
GI CANCER
Analysis of clinicopathological and immunohistochemical parameters and correlation of outcomes in gastrointestinal stromal tumors
Vaibhav Kumar Varshney, Rakesh Kumar Gupta, Sundeep Singh Saluja, Ila Tyagi, Pramod Kumar Mishra, Vineeta V Batra
April-June 2019, 56(2):135-143
DOI:10.4103/ijc.IJC_352_18  PMID:31062732
INTRODUCTION: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. We analyzed the clinicopathological features, resectability, immunohistochemical markers, and various factors predictive of disease recurrence and survival. MATERIALS AND METHODS: Retrospective analysis of prospectively maintained database of GIST patients managed from 2005 to 2016 was done. Size, site, malignant potential, nuclear pleomorphism, histopathological variety, immunohistochemical markers, type of surgery, and adjuvant imatinib therapy were analyzed. RESULTS: Ninety-two patients with GIST were analyzed. Immunohistochemistry showed positivity for c-kit (82.4%), DOG1 (75%), and PDGFR-α (79%). Among 16 patients with c-kit-negative tumors, 10 patients were positive for DOG1, PDGFR-α, or both. The most common primary site was stomach (44, 47.8%) followed by small bowel (17, 18.5%) and duodenum (14, 15.2%). Of 92 patients, 80 (87%) underwent R0 resection with organ sparing resection in 56 (70%) patients. Seventeen (21.3%) patients showed recurrence at a median follow-up of 6 years. Median and 5-year overall survival (OS) was 36 months (12–120) and 75%, respectively, and 5-year RFS was 81.8%. On univariate analysis, size, mitotic activity, malignant potential, and nuclear pleomorphism were predictors of recurrence. However, on multivariate analysis, only nuclear pleomorphism was significant. CONCLUSIONS: GISTs had a wide spectrum of presentation, and immunohistopathological features with organ sparing resection were conceivable in maximum. Nuclear pleomorphism may be considered as an important variable to predict recurrence in addition to malignant potential of tumors.
  399 113 -
BREAST CANCER
Optimization of sentinel lymph node identification techniques in the Indian setting: A randomized clinical trial
V Seenu, Suhani Suhani, Anurag Srivastava, Rajinder Parshad, Sandeep Mathur, Rakesh Kumar
April-June 2019, 56(2):114-118
DOI:10.4103/ijc.IJC_163_18  PMID:31062728
INTRODUCTION: The recommended technique of sentinel lymph node biopsy (SLNB) in breast cancer is a combination of blue dye and radiotracer. In the Indian scenario, SLNB is still not routinely practiced due to lack of nuclear medicine facilities and unavailability of isosulfan blue or patent blue violet (PBV). This study was conducted for optimizing SLN identification techniques by comparing the identification rate using PBV and methylene blue (MB) in combination with radiotracer. MATERIALS AND METHODS: Single-blinded two-arm parallel design randomized control trial was conducted at an apex teaching and research medical institute in India. Patients with axillary LN–negative breast cancer were included. Blue dye and radio tracer were injected preoperatively, and SLNB was performed using a combination technique. Frozen section was performed. Demographic, clinical, radiological, operative, and histopathological data were recorded. Descriptive statistics were used to represent patient characteristics. Baseline characteristics for entire cohort and between groups were compared using Student's t-test for quantitative variables and Chi-square test for qualitative variables. RESULTS: A total of 119 patients were randomized for mapping with MB and 118 patients with PBV between 2011 and 2015. SLN was identified in 116 patients with MB and 115 with PBV. SLN identification proportions were 97.4% (MB) and 96.6% (PBV). In patients undergoing axillary lymph node dissection, concordance with SLNB was 98.5% and 96.61% in MB and PBV, respectively. False-negative proportion for MB was 2.56% and 7.69% for PBV, respectively. The cost of MB is about INR 15 per ~10-mL vial. The cost of PBV is approximately ~$91 per ampoule (equivalent to approximately INR 8190). CONCLUSION: SLNB using MB can be recommended as the technique of choice in low-resource settings.
  348 137 -
CASE REPORTS
Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases
Ozturk Ates, Suayib Yalcin
April-June 2019, 56(2):176-179
DOI:10.4103/ijc.IJC_430_18  PMID:31062740
Rat sarcoma viral oncogene homolog (RAS) and B-Raf murine sarcoma viral oncogene homolog B1 (BRAF) are members of the same signaling pathway (RAS-RAF-mitogen-activated protein kinase (MAPK) in colorectal cancer (CRC). It is generally assumed that BRAF mutations are seen only with wild-type RAS in CRC. But RAS and BRAF are not mutually exclusive. We have identified concomitant BRAF and RAS mutations in seven patients. DNA was extracted from formalin-fixed paraffin-embedded tumor tissue and the mutation status of the RAS gene (exons 2, 3, 4) and BRAF (exon 15 V600, V597) was assessed using a polymerase chain reaction enzyme-linked mini sequence assay-based DNA sequencing method. Three patients harbored Kirsten rat sarcoma viral oncogene homolog (KRAS) with a codon 13 mutation (gly13asp) along with a BRAF variation of L597V in exon 15 (p. leu597val, c.1789C>G (CTA>GTA). Two patients harbored KRAS with codon 12 mutations; one harbored the gly12val mutation with a variation of leu597val in the BRAF exon 15 codon, the other harbored a gly12asp mutation with p. leu597val, c.1789C>G (CTA>GTA) in the BRAF exon 15 codon. One patient harbored a codon 117 mutation with a BRAF V600E mutation. The last patient harbored a NRAS exon 2 (gly12asp) mutation with the GGT/GAT, V600G mutation in the BRAF exon 15 codon. Consequently, concomitant KRAS and BRAF mutations are very rare. Although it is known that the survival of concomitant RAS/BRAF mutation carriers is generally poor, we have shown that survival of concomitant RAS/BRAF mutation carriers is variable.
  356 75 -
GI CANCER
Association of serum level of vitamin D and VDR polymorphism Fok1 with the risk or survival of pancreatic cancer in Egyptian population
Amal Ahmed Mohamed, Ahmed Moustafa Aref, Soha M Talima, Reham A A Elshimy, Shawkat S Gerges, Mohamed Meghed, Fawkia Eissa Zahran, Eman H EL-Adawy, Sherief Abd-Elsalam
April-June 2019, 56(2):130-134
DOI:10.4103/ijc.IJC_299_18  PMID:31062731
BACKGROUND AND AIMS: Pancreatic cancer (PC) is the fourth most common cause of death from cancer in Egypt. Few studies have been conducted to assess the relationship between vitamin D serum level and vitamin D receptor (VDR) polymorphisms with the survival of PC patients. This is the first study in Egypt to investigate the association of the status of vitamin D serum level and genotypic distribution of single nucleotide polymorphisms (SNP) Fok1 with the risk of developing PC and whether they could detect survival or not. PATIENTS AND METHODS: The study included a total of 47 PC cases that were histopathologically proven to have PC, and 37 controls that were attending at the same time for investigation but proved that they were all PC free. Pre-diagnostic concentrations of vitamin D and VDR polymorphism Fok1 were assessed from all participants in the study. RESULTS: There was a 1.5-fold increase in the serum level of vitamin D in PC patients when compared to non-PC subjects. Regarding VDR Fok1, polymorphism distribution in PC was CC (Wild Type) 26 (55.3%), CT 16 (34%), and TT 5 patients (10.7%). For the control group, CC was found in 24 (64.8%), CT in 12 (32.4%), and TT genotype was found only in one individual 1 (2.8%) with no statistically significant difference between the two studied groups (P 0.72). CONCLUSION: Low serum vitamin D or VDR-SNP is not a risk factor for PC in Egyptian patients. Recommendations to increase vitamin D concentrations in healthy persons for the prevention of cancer and improving overall survival should be carefully considered.
  330 99 -
HAEMATOLOGIC MALIGNANCY
Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia
Meiqing Lei, Limin Liu, Zhiming Wang, Depei Wu
April-June 2019, 56(2):167-172
DOI:10.4103/ijc.IJC_392_18  PMID:31062738
BACKGROUND: Acute myeloid leukemia (AML) patients with non-remission (NR) after the first cycle of standard induction chemotherapy remain a challenge owing to poor response and tolerance to re-induction regimen. We retrospectively evaluated the efficacy and safety of three regimens in AML patients refractory to the first course of standard induction regimen. MATERIALS AND METHODS: The three regimens consisted of (1) High-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor (HD-CAG) regimen (n = 44); (2) intermediate/high-dose cytarabine (I/HDAC) regimen (n = 30); and (3) standard-dose cytarabine (SDAC) combination regimen that was identical to the first course of standard induction regimen (n = 27). RESULTS: Results indicated that after the second course, the overall response (OR), i.e., complete remission [CR]+partial remission [PR]) rates in HD-CAG was higher than in the I/HDAC group (84.1% vs. 56.7%, P = 0.009), whereas the CR rates among 3 groups were not statistically different (P = 0.541). Meanwhile, the proportion of subjects reporting certain adverse effects in the HD-CAG group was lower than the I/HDAC or SDAC groups. There were no significant differences in overall survival (OS) and disease-free survival (DFS) rates among the 3 groups (P = 0.881 and P = 0.872, respectively). CONCLUSION: Our preliminary results indicate that HD-CAG regimen may represent a better alternative option for AML patients with NR after the first course of standard induction chemotherapy.
  361 67 -
CASE REPORTS
Severe hyperlipidemia in a case of acute lymphoblastic leukemia
Rimjhim Sonowal, Vineeta Gupta
April-June 2019, 56(2):180-181
DOI:10.4103/ijc.IJC_724_18  PMID:31062741
Severe hyperlipidemia (>1000 mg/dL) at initial presentation of acute lymphoblastic leukemia (ALL) is rare. Cases of hyperlipidemia during therapy for childhood ALL where they were secondary to L-asparaginase or steroids have been described. This is a case report of a one-and-half-year-old boy who presented to us with fever, abdominal distension, severe pallor, and hepatosplenomegaly. Although his investigations were suggestive of ALL, the initial blood samples were found to be grossly lipemic. The lipid profile was abnormal, showing severe hypertriglyceridemia (serum triglycerides 1552 mg/dL). High-density lipoprotein and low-density lipoprotein levels were low, but there were raised very low-density lipoprotein level and serum lactate dehydrogenase (18117 U/L). The patient was started on induction of remission with careful monitoring of biochemical parameters. Abnormal lipid levels declined gradually with normalization of the levels at the end of one week of chemotherapy. No further complications were encountered during the course of induction of remission.
  324 66 -
Medullary and papillary thyroid carcinomas in a patient with a C634Y mutation in the RET proto-oncogene: A case report
Yan Ding, Jun Feng, Xun-hua Xu, Jun Yao, Rong-Biao Ying
April-June 2019, 56(2):173-175
DOI:10.4103/ijc.IJC_472_18  PMID:31062739
A 41 year old man presented with a familial history of multiple endocrine neoplasia type 2A (MEN2A) and severe hypertension. Rearranged during transfection (RET) gene sequencing confirmed a Cys634Tyr mutation of TGC to TAC. Total thyroidectomy and bilateral neck dissection were performed and the pathological assessment revealed a medullary thyroid carcinoma (MTC), 0.6 cm in size on the right side (number of lymph nodes: 0/2, 0/15, 0/12, and 0/8 in areas VI, II, III, and IV, respectively) and a papillary thyroid carcinoma (PTC), 0.2 cm in size on the left side (numbers of lymph nodes: 2/6, 0/3, 0/10, and 0/6 in areas VI, II, III, and IV, respectively). There were no pathological changes in the MTC observed in the thyroid tissues on the left side. We believe that the follow-up of patients with both MTC and PTC should utilize a combination of the respective principles for rational disease reassessment.
  294 88 -
LETTERS TO THE EDITOR
Gall bladder cancer in Delhi - some thoughts
Manigreeva Krishnatreya
April-June 2019, 56(2):182-182
DOI:10.4103/ijc.IJC_521_18  PMID:31062743
  309 67 -
NEUROONCOLOGY
Fractionated stereotactic radiosurgery for locally recurrent brain metastases after failed stereotactic radiosurgery
Ferrat Dincoglan, Omer Sager, Selcuk Demiral, Hakan Gamsiz, Bora Uysal, Elif Onal, Ayca Ekmen, Bahar Dirican, Murat Beyzadeoglu
April-June 2019, 56(2):151-156
DOI:10.4103/ijc.IJC_786_18  PMID:31062735
AIMS AND BACKGROUND: There is scant data on the utility of repeated radiosurgery for management of locally recurrent brain metastases after upfront stereotactic radiosurgery (SRS). Most studies have used single-fraction SRS for repeated radiosurgery, and the use of fractionated stereotactic radiosurgery (f-SRS) in this setting has been poorly addressed. In this study, we assessed the utility of f-SRS for the management of locally recurrent brain metastases after failed upfront single-fraction SRS and report our single-center experience. METHODS AND STUDY DESIGN: A total of 30 patients receiving f-SRS for locally recurrent brain metastases after upfront single-fraction SRS at our department between September 2011 and September 2017 were retrospectively evaluated for local control (LC), toxicity, and overall survival outcomes. RESULTS: Median age and Karnofsky performance status were 57 (range: 38–78 years) and 80 (range: 70–100) at repeated radiosurgery (SRS2). The median time interval between the two radiosurgery applications was 13.5 months (range: 3.7–49 months). LC after SRS2 was 83.3%. Radionecrosis developed in 4 of the 30 lesions after SRS2, and total rate of radionecrosis was 13.3%. Statistical analysis revealed that the volume of planning target volume (PTV) at SRS2 was significantly associated with radionecrosis (P = 0.014). The volume of PTV was >13 cm3 at SRS2 in all patients with radionecrosis. CONCLUSION: A repeated course of radiosurgery in the form of f-SRS may be a viable therapeutic option for the management of locally recurrent brain metastases after failed upfront SRS with high LC rates and an acceptable toxicity profile despite the need for further supporting evidence.
  252 70 -
COMMENTARY
Ketamine for post-thoracotomy pain: An old drug with new horizons
Rohini Dattatri, Nishkarsh Gupta
April-June 2019, 56(2):187-188
DOI:10.4103/ijc.IJC_18_19  PMID:31062747
  252 64 -
MCQS
MCQs for “Analysis of clinicopathological and immunohistochemical parameters and correlation of outcomes in gastrointestinal stromal tumors”
HS Darling, S Jayalakshmi, Pradeep Jaiswal
April-June 2019, 56(2):144-145
DOI:10.4103/ijc.IJC_354_19  PMID:31062733
  229 62 -
LETTERS TO THE EDITOR
The rising incidence of papillary thyroid cancer: More cancers or more assessments?
Francesca Galuppini, Gianmaria Pennelli, Massimo Rugge
April-June 2019, 56(2):183-184
DOI:10.4103/ijc.IJC_483_18  PMID:31062744
  233 49 -
Ketamine-an essential component of postoperative pain management following oncosurgeries: TMH experience
Pritish P Kumbhare, Sumitra G Bakshi, Renuka Purohit
April-June 2019, 56(2):186-186
DOI:10.4103/ijc.IJC_320_18  PMID:31062746
  214 51 -
NEWS IN BRIEF
News in brief

April-June 2019, 56(2):192-194
DOI:10.4103/ijc.IJC_336_19  
  179 64 -
BOOK REVIEW
The bright hour: A memoir of living and dying
Nilakshi Biswas
April-June 2019, 56(2):191-191
DOI:10.4103/ijc.IJC_195_19  PMID:31062749
  200 38 -
LETTERS TO THE EDITOR
Cancer surveillance of the indigenous population in India: Much needed
Mukund Namdev Sable, Tushar Mishra
April-June 2019, 56(2):182-183
DOI:10.4103/ijc.IJC_480_18  PMID:31062742
  168 61 -
NARRATIVE
The wait of expectation
Vidya Viswanath, Leela Digumarti
April-June 2019, 56(2):189-190
DOI:10.4103/ijc.IJC_24_19  PMID:31062748
  178 50 -
LETTERS TO THE EDITOR
Renal metastasis of lung cancer mimicking renal infarction
Keisuke Watanabe, Kentaro Yumoto, Takeshi Kaneko
April-June 2019, 56(2):185-185
DOI:10.4103/ijc.IJC_512_18  PMID:31062745
  156 49 -
PHARMACO-ECONOMICS/CHEMOTHERAPY
Financial audit of wastage of anticancer drugs: Pilot study from a tertiary care center in India
Veena Reshma D'Souza, Princy Louis Palatty, Thomas George, Mohammed Adnan, Suresh Rao, Manjeshwar Shrinath Baliga
April-June 2019, 56(2):146-150
DOI:10.4103/ijc.IJC_169_18  PMID:31062734
PURPOSE: Drug wastage is a major concern in oncology where costs of antineoplastic drugs are exorbitant, and the disposal of toxic drugs increases the chances of occupational hazards to healthcare and sanitary workers and environmental pollution at the site of disposal. The principal objective of this study was to ascertain the extent of drug wastage and calculate its financial costs. MATERIALS AND METHODS: This was a prospective pilot study conducted to ascertain the quantity of drug wastage in a tertiary care hospital. This pilot study was conducted in day care and inpatient facilities in February 2016. The prescription of cytotoxic drugs, recommended dose, the quantity used, and remainder (waste) left were recorded from the nurses and pharmacy files of the hospital. Cost evaluation of the actual use and the waste was undertaken and an audit was conducted to understand in which anticancer drug the maximum wastage was generated. RESULTS: The results of this study indicated that 6.1% of the total amount of reconstituted drugs was wasted. The highest drug wastage was observed in trastuzumab (29.55%), followed by etoposide (20.4%), dacarbazine (17.14%), daunorubicin (16.67%), and carboplatin (11.29%). Cost analysis showed that the total cost of the drug issued during the study period was Rs. 1,294,975 and the cost of drug wastage amounted to Rs. 143,820 (11.1%). CONCLUSION: To the best of authors' knowledge, this is the first study from India and the results indicate that the financial impact of anticancer drug wastage was substantial. Attempts should be directed at minimizing the wastage and cost savings without risking patients' treatment regimen and administering effective dose schedule.
  98 53 -
GYNECOLOGIC ONCOLOGY
Effects of some characteristics of gynecological cancer diagnosis and treatment on women's sexual life quality
Buse Güler, Samiye Mete
April-June 2019, 56(2):157-162
DOI:10.4103/ijc.IJC_127_18  PMID:31062736
BACKGROUND: Gynecological cancers can cause changes in women's sexual life. AIM: The aim of this study was to evaluate the factors affecting sexual quality of life (SQoL) of women with gynecological cancer. MATERIALS AND METHODS: A descriptive, cross-sectional study design was used. The study was conducted on 276 women with gynecological cancers in Turkey. Information form and SQoL scale was used in the study. The data were evaluated using Mann–Whitney U-test and Kruskal–Wallis test. RESULTS: The SQoL mean score was 68.83 ± 21.17. There was no significant difference in the SQoL mean score according to the individual/sociodemographic characteristics or gynecological cancer-related characteristics. However, it was found that the difference was due to higher SQoL score in the group with a diagnosis time of 25 months and above (KW (Χ2) = 6.356, P = 0.046). CONCLUSION: The reason for significant difference in the SQoL mean score according to diagnosis over time might be that women adapted to cancer diagnosis. For this reason, the SQoL of women with a diagnosis time of < 25 months should be assessed and these women should be supported.
  93 46 -
THORAX
Efficacy and tolerance of thoracic radiotherapy in the oldest old patients: A case series
Benoîte Méry, Chloe Rancoule, Avi Assouline, Lounis Aissou, Alexander T Falk, Pierre Auberdiac, Alexis Vallard, Cyrus Chargari, Nicolas Magn
April-June 2019, 56(2):163-166
DOI:10.4103/ijc.IJC_346_18  PMID:31062737
BACKGROUND: There are only scarce data on the management of nonagenarians with lung cancer, and more particularly on the place of radiation therapy. The aim of the present study was to retrospectively evaluate the efficacy and tolerance of radiotherapy (RT) in nonagenarians with thoracic cancer. PATIENTS AND METHODS: Records from RT departments from four institutions were reviewed to identify patients 90 years old of age and older undergoing RT over the past decade for thoracic cancer and more particularly lung cancer. Tumors' characteristics as well as treatment specificities and its intent were examined. RESULTS: Thirteen patients receiving RT courses were identified, mean age 91.9 years. Treatment was given with curative and palliative intent in 15.4% and 84.6%, respectively. The median total prescribed dose was 30 Gy (4–70). The median number of fractions was equal to 10 (1-35). The median dose received for each fraction was 3 Gy (1.7–7). RT could not be completed in 2 patients (15.4%). At last follow-up, 11 patients (76.9%) were deceased, cancer being the cause of death for 90% of them. Most toxicities were grade 1 or 2. Two patients (15.4% of cases) have developed grade 2 toxicity during treatment. One patient (7.7% of cases) experienced an acute grade 3 toxicity. CONCLUSION: The study shows that RT for thoracic cancer is feasible in nonagenarians. Although the definitive benefit of RT could not be addressed here, hypofractionated therapy allowed a certain measure of control with acceptable side effects.
  67 31 -
  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow